Tag:
erectile dysfunction
Latest Headlines
Latest Headlines
Pfizer combats online fakes with direct-to-patient Viagra sales
Pfizer ($PFE) is testing the online-sales waters with a new program to sell Viagra directly to consumers. It's a natural choice: Makers of erectile dysfunction drugs have been working on packaging and formulation changes to make it easier--and more discreet--for men to use them.
Study: ED drugmakers aren't properly policing their TV ads
Embarrassed by the ads for erectile dysfunction drugs that pop up at the most inopportune moments? A new study found that the television commercials are indeed airing at family-viewing times--contrary to drugmakers' express promises to refrain.
Acorda's drug treats nerve damage-related ED in preclinical test
Acorda Therapeutics' new neuregulin drug helped treat erectile dysfunction in rats with nerve damage, according to preclinical data the company presented at a recent conference.
Acorda's drug treats nerve damage-related ED in preclinical test
Acorda Therapeutics' new neuregulin drug helped treat erectile dysfunction in rats with nerve damage, according to preclinical data the company presented at a recent conference.
Vivus gets ED drug approval, spurring fresh talk of a deal
Vivus has won its first drug approval. The FDA issued word this afternoon that it had stamped its OK on Stendra (avanafil), an erectile dysfunction treatment designed to spur a quicker response for men.
Ampio to seek foreign OKs for premature ejaculation drug
Ampio Pharmaceuticals ($AMPE) is gearing up to seek international regulatory approval for its drug to treat premature ejaculation. The company disclosed Dec. 5 that it is preparing for this, in part,
Lilly's ED treatment Cialis wins prostate indication
Eli Lilly ( $LLY ) just won FDA approval for an enlarged-prostate treatment. That's a bit of good news that only goes so far, as the market for benign prostatic hyperplasia treatments is rather full.
Viagra 2.0: Delivered via nanotech patch?
Viagra delivered via a patch with nanocarriers might work better than the blue pill for erectile dysfunction, according to researchers in Egypt. While oral delivery does work, there is too long a
Vivus readies NDA as Ph3 trial hits goals for ED drug
Mountain View, CA-based Vivus ( $VVUS ) says that its experimental erectile dysfunction drug avanafil hit its goals in a Phase III study. And Vivus, which has been struggling to respond to the FDA's
ED drugmakers look to new formulations
When the patent cliff looms, what do makers of erectile dysfunction remedies turn to? Consumer psychology. As the New York Times reports, Pfizer and Bayer both are reformulating their blockbuster ED
